VPC171

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

VPC171 是一种新型腺苷 A1 受体正变构调节剂 (PAM)。

VPC171 is a novel adenosine A1 receptor positive allosteric modulator (PAM).(In Vivo):VCP171 produced a greater inhibition of eEPSC amplitude of nerve-injury versus control animals in both lamina I and lamina II neurons.

——

VCP171 (10 μM) reduces AMPAR-mediated evoked excitatory postsynaptic current (eEPSCs) in lamina I cells in sham and nerve-injured animals; increases paired pulse ration in cells from sham control animals; is significantly more effective in Lamina II neurons from nerve-injured animals than sham controls. Animal Model:Neurons from male Sprague-Dawley rats (5-6 weeks; performed a partial nerve ligation (PNL) of the left sciatic nerve to create neuropathic pain model)Dosage:10 μM Administration:0-30 min Result:Reduced AMPAR-mediated evoked excitatory postsynaptic current (eEPSCs) in Lamina I cells in sham (13±2%, n=7 cells) and nerve-injured animals (24±4%, n=8 cells) compared with predrug controls; increased paired pulse ration in cells from sham control animals; was significantly more effective in Lamina II neurons from nerve-injured animals than sham controls.

VPC 171 | VPC-171

Apoptosis

Adenosine Receptor

Sirtuin

——

——

1018830-99-3

347.36

C18H12F3NOS

>98% (HPLC)

——

Nc1scc(c1C(=O)c1ccccc1)-c1cccc(c1)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years